These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25185192)

  • 41. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
    Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
    Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
    Anantharaman A; Friedlander TW
    Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
    Martinez-Ariza G; Hulme C
    Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of novel androgen receptor antagonists based on the structure of darolutamide.
    Xu Q; Zhang Z; Huang C; Bao Q; Zhang R; Wu M; Xiao X; Han X; Li X; Zhou J
    Bioorg Chem; 2022 Jul; 124():105829. PubMed ID: 35490582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
    Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
    Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
    Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
    Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
    Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
    Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Darolutamide for non-metastatic, castration-resistant prostate cancer.
    Burki T
    Lancet Oncol; 2019 Mar; 20(3):e139. PubMed ID: 30799257
    [No Abstract]   [Full Text] [Related]  

  • 51. Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn't Gold.
    Di Lorenzo G; Autorino R
    Eur Urol; 2020 Nov; 78(5):647-649. PubMed ID: 32800724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Darolutamide: First Approval.
    Markham A; Duggan S
    Drugs; 2019 Nov; 79(16):1813-1818. PubMed ID: 31605368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.
    Christensen BR; Barata PC; Ledet EM; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2019 Dec; 17(6):476-479. PubMed ID: 31537449
    [No Abstract]   [Full Text] [Related]  

  • 54. Commentary on "Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer".
    Chueh SC
    South Med J; 2015 Apr; 108(4):229. PubMed ID: 25871993
    [No Abstract]   [Full Text] [Related]  

  • 55. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide added to leuprolide in a 73-year-old patient.
    Landau DA
    Clin Adv Hematol Oncol; 2022 Jun; 20 Suppl 10(6):1-8. PubMed ID: 35772002
    [No Abstract]   [Full Text] [Related]  

  • 56. Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Asian J Androl; 2020; 22(1):76-78. PubMed ID: 31249268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interpreting the impact of apalutamide on overall survival among patients with non-metastatic castration-resistant prostate cancer.
    McCaw ZR; Wei LJ; Ludmir EB
    Ann Oncol; 2020 Mar; 31(3):438-440. PubMed ID: 32067688
    [No Abstract]   [Full Text] [Related]  

  • 58. Prostate cancer: CYP17A1 inhibitor failure-lessons for future drug development.
    Sharifi N
    Nat Rev Urol; 2015 May; 12(5):245-6. PubMed ID: 25823374
    [No Abstract]   [Full Text] [Related]  

  • 59. Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer.
    Alghazo O; Thangasamy I; Sathianathen N; Murphy DG
    Eur Urol; 2019 Oct; 76(4):536-537. PubMed ID: 31101535
    [No Abstract]   [Full Text] [Related]  

  • 60. Neutrophil to lymphocyte ratio: another drop in the ocean of CRPC biomakers?
    Castro E; Lozano R; Olmos D
    Ann Oncol; 2015 Apr; 26(4):622-623. PubMed ID: 25646369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.